Key result
Long-term treatment with ketanserin significantly decreased blood pressure and blood pressure variability, and prevented target organ damage in spontaneously hypertensive rats.
Why the study?
Does long-term treatment with ketanserin reduce blood pressure variability and end-organ damage in spontaneously hypertensive rats?
Does long-term treatment with ketanserin reduce blood pressure variability and end-organ damage in spontaneously hypertensive rats?
Answers are grounded in this paper and cite their sources.
In spontaneously hypertensive rats, long-term ketanserin treatment reduced blood pressure variability and protected against end-organ damage, an effect not seen with hydralazine despite similar blood pressure lowering.
It has been proposed that instability of blood pressure may produce organ damage. Ketanserin is an anti-hypertensive drug with an ability to reduce blood pressure variability (BPV) in acute experiments in spontaneously hypertensive rats (SHRs). The present work was designed to observe the effects of long-term treatment with ketanserin on BPV and end-organ damage in SHRs. Ketanserin was mixed in rat chow at an estimated dose of 10 mg/kg/d. After 5 months of drug administration, BP was continuously recorded in conscious, freely moving rats for 24 h. The heart, kidneys, and abdominal aorta were then isolated and examined by using histologic methods and computer image analysis. In another work, the effects of hydralazine (40 mg/kg/d, for 5 months) on BP, BPV, and organ damage were observed in SHRs. Ketanserin significantly decreased BP and BPV, ameliorated impaired arterial baroreflex function, and significantly prevented the target organs of SHRs from being damaged. This preventive effect was characterized by decrease in left ventricular hypertrophy, diminution of glomerulus damage, and amelioration in vascular lesion. Hydralazine decreased BP but did not lower BPV. No organ protection was found in hydralazine-treated rats. In conclusion, long-term treatment with ketanserin reduced hypertensive organ damage. Lowering BP, decreasing BPV, and ameliorating arterial baroreflex function may contribute together to this effect.
No takes yet. Share an insight, caveat, or question.
Du et al. (2003) studied Hypertension. Ketanserin vs. Hydralazine was evaluated on Blood pressure variability (BPV) and end-organ damage. Long-term treatment with ketanserin significantly decreased blood pressure and blood pressure variability, and prevented target organ damage in spontaneously hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: